Daphne Macbruce, MD
Pulmonary Disease · Fort Smith, ARNPI 1780966937
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,433 of the $9,624 with a category attached, or 87.6%. It is spread thinly across 42 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 487 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Olympus Corporation Of The Americas$887
- Actelion Pharmaceuticals US, Inc.$606
- Genentech USA, Inc.$476
- plus $4K from 36 others
What the payments were for
- Travel & lodging$8329%
- Food & beverage$8,43388%
- Education$3594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINGLE USE SUCTION VALVE (Sterile)$729
- Impella$148
- AREXVY$125
- BREZTRI$125
- SYMBICORT$120
How this compares
$9,624 in reported general payments places this provider in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $463,250 |
| OpsumitMacitentan | 35 | $446,888 |
| UptraviSelexipag | 13 | $232,991 |
| XolairOmalizumab | 32 | $100,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 122 | $93,169 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $53,886 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $33,508 |
| Spiriva RespimatTiotropium Bromide | 48 | $33,491 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $32,539 |
| Tadalafil | 12 | $27,230 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $25,572 |
| XareltoRivaroxaban | 28 | $23,746 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 39 | $19,294 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,491 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 149 | $4,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $606 | $679,88048 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,063 | $530,249146 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,458 | $172,627279 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,438 | $56,324100 claims |
| Johnson & JohnsonXarelto | $54 | $23,74628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fort Smith
- Arturo MeadeFort Smith$67K
- Adebayo FasanyaFort Smith$8K
- Muhammad MirFort Smith$4K
- Sarikun TjandraFort Smith$3K
- Francisco TamayoFort Smith$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.